These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. A Microdosing Study with Kulterer OC; Pfaff S; Wadsak W; Garstka N; Remzi M; Vraka C; Nics L; Mitterhauser M; Bootz F; Cazzamalli S; Krall N; Neri D; Haug AR J Nucl Med; 2021 Mar; 62(3):360-365. PubMed ID: 32680925 [No Abstract] [Full Text] [Related]
26. Molecular imaging with a fluorescent antibody targeting carbonic anhydrase IX can successfully detect hypoxic ductal carcinoma in situ of the breast. van Brussel AS; Adams A; Vermeulen JF; Oliveira S; van der Wall E; Mali WP; van Diest PJ; van Bergen En Henegouwen PM Breast Cancer Res Treat; 2013 Jul; 140(2):263-72. PubMed ID: 23860929 [TBL] [Abstract][Full Text] [Related]
27. Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma. Cheal SM; Punzalan B; Doran MG; Evans MJ; Osborne JR; Lewis JS; Zanzonico P; Larson SM Eur J Nucl Med Mol Imaging; 2014 May; 41(5):985-94. PubMed ID: 24604591 [TBL] [Abstract][Full Text] [Related]
28. Carbonic anhydrase IX (CAIX) does not differentiate between benign and malignant mesothelium. Ananthanarayanan V; Tretiakova M; Husain AN; Krausz T; Antic T Am J Clin Pathol; 2014 Jul; 142(1):82-7. PubMed ID: 24926090 [TBL] [Abstract][Full Text] [Related]
29. Radionuclide and Fluorescence Imaging of Clear Cell Renal Cell Carcinoma Using Dual Labeled Anti-Carbonic Anhydrase IX Antibody G250. Muselaers CH; Rijpkema M; Bos DL; Langenhuijsen JF; Oyen WJ; Mulders PF; Oosterwijk E; Boerman OC J Urol; 2015 Aug; 194(2):532-8. PubMed ID: 25686542 [TBL] [Abstract][Full Text] [Related]
30. Feasibility of Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting of Malignant Tumors. Honarvar H; Westerlund K; Altai M; Sandström M; Orlova A; Tolmachev V; Karlström AE Theranostics; 2016; 6(1):93-103. PubMed ID: 26722376 [TBL] [Abstract][Full Text] [Related]
31. Quantitative Imaging of the Hypoxia-Related Marker CAIX in Head and Neck Squamous Cell Carcinoma Xenograft Models. Huizing FJ; Hoeben BAW; Franssen GM; Boerman OC; Heskamp S; Bussink J Mol Pharm; 2019 Feb; 16(2):701-708. PubMed ID: 30550290 [TBL] [Abstract][Full Text] [Related]
32. Construction of ultrasonic nanobubbles carrying CAIX polypeptides to target carcinoma cells derived from various organs. Zhu L; Guo Y; Wang L; Fan X; Xiong X; Fang K; Xu D J Nanobiotechnology; 2017 Sep; 15(1):63. PubMed ID: 28962657 [TBL] [Abstract][Full Text] [Related]
33. 188Re-ZHER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors: preclinical assessment. Altai M; Wållberg H; Honarvar H; Strand J; Orlova A; Varasteh Z; Sandström M; Löfblom J; Larsson E; Strand SE; Lubberink M; Ståhl S; Tolmachev V J Nucl Med; 2014 Nov; 55(11):1842-8. PubMed ID: 25278516 [TBL] [Abstract][Full Text] [Related]
34. Identification of Carbonic Anhydrase IX as a Novel Target for Endoscopic Molecular Imaging of Human Bladder Cancer. Wang J; Fang R; Wang L; Chen G; Wang H; Wang Z; Zhao D; Pavlov VN; Kabirov I; Wang Z; Guo P; Peng L; Xu W Cell Physiol Biochem; 2018; 47(4):1565-1577. PubMed ID: 29949785 [TBL] [Abstract][Full Text] [Related]
35. Vimentin over-expression and carbonic anhydrase IX under-expression are independent predictors of recurrence, specific and overall survival in non-metastatic clear-cell renal carcinoma: a validation study. Ingels A; Hew M; Algaba F; de Boer OJ; van Moorselaar RJ; Horenblas S; Zondervan P; de la Rosette JJ; Pilar Laguna Pes M World J Urol; 2017 Jan; 35(1):81-87. PubMed ID: 27207480 [TBL] [Abstract][Full Text] [Related]
36. Prognostic value of the co-expression of carbonic anhydrase IX and vascular endothelial growth factor in patients with clear cell renal cell carcinoma. Phuoc NB; Ehara H; Gotoh T; Nakano M; Kamei S; Deguchi T; Hirose Y Oncol Rep; 2008 Sep; 20(3):525-30. PubMed ID: 18695901 [TBL] [Abstract][Full Text] [Related]
37. Acetazolamide-based [ More KN; Lee JY; Kim DY; Cho NC; Pyo A; Yun M; Kim HS; Kim H; Ko K; Park JH; Chang DJ Bioorg Med Chem Lett; 2018 Mar; 28(5):915-921. PubMed ID: 29422388 [TBL] [Abstract][Full Text] [Related]
38. Carbonic Anhydrase IX in Renal Cell Carcinoma, Implications for Disease Management. Courcier J; de la Taille A; Nourieh M; Leguerney I; Lassau N; Ingels A Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32998233 [TBL] [Abstract][Full Text] [Related]
39. Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitors. Lou Y; McDonald PC; Oloumi A; Chia S; Ostlund C; Ahmadi A; Kyle A; Auf dem Keller U; Leung S; Huntsman D; Clarke B; Sutherland BW; Waterhouse D; Bally M; Roskelley C; Overall CM; Minchinton A; Pacchiano F; Carta F; Scozzafava A; Touisni N; Winum JY; Supuran CT; Dedhar S Cancer Res; 2011 May; 71(9):3364-76. PubMed ID: 21415165 [TBL] [Abstract][Full Text] [Related]
40. Feasibility of Affibody-Based Bioorthogonal Chemistry-Mediated Radionuclide Pretargeting. Altai M; Perols A; Tsourma M; Mitran B; Honarvar H; Robillard M; Rossin R; ten Hoeve W; Lubberink M; Orlova A; Karlström AE; Tolmachev V J Nucl Med; 2016 Mar; 57(3):431-6. PubMed ID: 26659353 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]